(Q37893639)

24 August 2017

1 reference

title

Vilazodone: in major depressive disorder (English)

1 reference

24 August 2017

1 reference

ChEBI release 2020-05-28

James E Frampton

1

1 reference

24 August 2017

publication date

1 July 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

25

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

615-627

1 reference

https://scigraph.springernature.com/pub.10.2165/11207550-000000000-00000

24 August 2017

exact match

0 references

cites work

Posttraumatic stress disorder in the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Depression in the medically ill: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Blues from the neighborhood? Neighborhood characteristics and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

The future of psychopharmacology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Problems associated with long-term treatment with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Antidepressants: current strategies and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207550-000000000-00000

Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY-100635

21 January 2018

1 reference

12 December 2020

First-line pharmacotherapies for depression - what is the best choice?

1 reference

12 December 2020

The burden of recurrent depression: causes, consequences, and future prospects

1 reference

12 December 2020

A critical review of pharmacotherapy for major depressive disorder.

1 reference

12 December 2020

Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.

1 reference

12 December 2020

EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties

1 reference

12 December 2020

The use of pindolol to potentiate antidepressant medication

1 reference

12 December 2020

Vilazodone: another novel atypical antidepressant drug

1 reference

12 December 2020

10.2165/11207550-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1024601314

0 references

1 reference